Perfil informativo no verificado por el centro
Construido a partir de registros públicos; no implica afiliación.
Sin afiliación: BiomedicalResearch.mx no afirma representar a este centro y no garantiza que este listado sea completo. Confirma siempre nombre, dirección, contacto y estatus en el registro oficial.
Variantes de nombre encontradas
- INCan - Instituto Nacional de Cancerología
- Instituto Nacional De Cancerologia
- Instituto Nacional De Cancerologia de Mexico
- Instituto Nacional de Cancerologia
- Instituto Nacional de Cancerologia (INCan) Mexico
- Instituto Nacional de Cancerologia de Mexico
- Instituto Nacional de Cancerologia. ( Site 0808)
- Instituto Nacional de Cancerología
- Instituto Nacional de Cancerología (INCan)
- Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de Cancerología
Estudios detectados
ReclutandoNCT07225309
A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer
Ver registro oficial ↗ReclutandoNCT07405801
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Ver registro oficial ↗ReclutandoNCT05646862
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Ver ficha informativaReclutandoNCT05879926
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ver registro oficial ↗ReclutandoNCT06790693
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ver registro oficial ↗ReclutandoNCT05929768
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Ver registro oficial ↗ReclutandoNCT06592924
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Ver registro oficial ↗ReclutandoNCT03678025
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Ver registro oficial ↗ReclutandoNCT07472517
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Ver registro oficial ↗ReclutandoNCT06765109
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ver registro oficial ↗ReclutandoNCT06452277
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ver registro oficial ↗ReclutandoNCT06181812
Pathogenic Variants in Genes Associated With Lung Adenocarcinoma
Ver registro oficial ↗ReclutandoNCT05713006
Alectinib Pharmacokinetic in Patients With NSCLC
Ver registro oficial ↗ReclutandoNCT07190248
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Ver registro oficial ↗ReclutandoNCT06477302
Scale of Therapeutic Adherence to Respiratory Rahabilitation for Lung Cancer
Ver registro oficial ↗ReclutandoNCT07192991
Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
Ver registro oficial ↗ReclutandoNCT05445791
Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations
Ver registro oficial ↗ReclutandoNCT02734069
Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC
Ver registro oficial ↗ReclutandoNCT06758401
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Ver registro oficial ↗ReclutandoNCT07195695
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Ver registro oficial ↗ReclutandoNCT06238882
Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.
Ver registro oficial ↗ReclutandoNCT05852990
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
Ver registro oficial ↗ReclutandoNCT06535451